- Home
- GGZ vs CGEN Comparison
GGZ vs CGEN Comparison
Compare GGZ & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGZ
- CGEN
- Stock Information
- Founded
- GGZ 2013
- CGEN 1993
- Country
- GGZ United States
- CGEN Israel
- Employees
- GGZ N/A
- CGEN N/A
- Industry
- GGZ Investment Managers
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GGZ Finance
- CGEN Health Care
- Exchange
- GGZ Nasdaq
- CGEN Nasdaq
- Market Cap
- GGZ 110.1M
- CGEN 125.3M
- IPO Year
- GGZ N/A
- CGEN 2000
- Fundamental
- Price
- GGZ $14.06
- CGEN $1.77
- Analyst Decision
- GGZ
- CGEN
- Analyst Count
- GGZ 0
- CGEN 0
- Target Price
- GGZ N/A
- CGEN N/A
- AVG Volume (30 Days)
- GGZ 12.8K
- CGEN 557.0K
- Earning Date
- GGZ 01-01-0001
- CGEN 11-10-2025
- Dividend Yield
- GGZ 5.39%
- CGEN N/A
- EPS Growth
- GGZ N/A
- CGEN N/A
- EPS
- GGZ 1.75
- CGEN N/A
- Revenue
- GGZ N/A
- CGEN $22,144,000.00
- Revenue This Year
- GGZ N/A
- CGEN N/A
- Revenue Next Year
- GGZ N/A
- CGEN $208.08
- P/E Ratio
- GGZ $6.79
- CGEN N/A
- Revenue Growth
- GGZ N/A
- CGEN N/A
- 52 Week Low
- GGZ $9.43
- CGEN $1.13
- 52 Week High
- GGZ $12.50
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- GGZ 46.93
- CGEN 52.38
- Support Level
- GGZ $13.99
- CGEN $1.63
- Resistance Level
- GGZ $14.34
- CGEN $1.75
- Average True Range (ATR)
- GGZ 0.20
- CGEN 0.14
- MACD
- GGZ 0.00
- CGEN -0.03
- Stochastic Oscillator
- GGZ 61.02
- CGEN 25.07
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.